Alnylam announces collaboration with novartis to explore targeted therapy to restore liver function

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, today announced a collaboration with novartis to leverage alnylam's proven, proprietary sirna technology to inhibit a target discovered at the novartis institutes for biomedical research, potentially leading to development of a treatment designed to promote the regrowth of functional liver cells and to provide an alternative to transplantation for patients with liver failure.
ALNY Ratings Summary
ALNY Quant Ranking